Journal of Nanomaterials / 2009 / Article / Tab 1

Review Article

Antibody-Conjugated Nanoparticles for Biomedical Applications

Table 1

Monoclonal antibodies approved for human therapy, their applications and data of approval by FDA and/or EMEA.

ProductCompanyApplicationsApproval

Muromomab (Orthoclone OKT3)Ortho Biotech, Inc. (Johnson & Johnson)Mouse IgG2a anti-CD3. Transplantation RejectionFDA 1986
EMEA 1987
Abciximab (ReoPro)Centocor B.V.Chimeric 7E3 directed against platelet glycoprotein IIb/IIIaFDA 1994
Nofetumomab (Verluma)Boehringer Ingelheim Pharma KGMouse Fab directed against glycoprotein 40 kD (expressed in several tumours). Conjugated to Tecnecio99FDA 1996
Imciromab-Pentetate (Myoscint)Centocor (Johnson & Johson)Mouse Fab-Indio111, directed against human heart miosinFDA 1996
Arcitumomab (CEA-Scan)Immunomedics Inc.Mouse Ig Fragment-Tecnecio99. Directed against carcinoembrionic antigenFDA 1996
EMEA 1996,
Retired 2005
Capromab Pendetide ProstaScintCytogen Corp.Mouse Ab-Indio111. Detection of prostate tumourFDA 1996
Daclizumab (Zenapax)Hoffman-LA Roche Inc.Humanized IgG1 anti-IL-2 . To avoid transplant rejectionFDA 1997
EMEA 1999
Rituximab (Rituxan)Genentech Inc.Chimeric Ig antiCD20 for Non-Hodgkin lymphomasFDA 1997
EMEA 1998
Basiliximab (Simulect)Novartis Phamaceutical Corp.Chimeric anti-IL-2 (CD25). To avoid renal transplantFDA 1998
EMEA 1999
Palivizaumab (Sinagis)Medimmune Inc.Humanized IgG1; respiratory syncitial virusFDA 1998
EMEA 1999
Trastuzumab (Herceptin )Genentech Inc.Humanized IgG anti-HER2; breast cancerFDA 1998
EMEA 2000
Remicade (Infliximab)Centocor (Johnson & Johnson)Chimeric anti TNF- . Rheumatoid arthritis, Crohn’s diseaseFDA 1998
EMEA 2002
Gemtuzumab Ozogamicin (Mylotarg)Wyeth AverstHumanized Ig anti CD33; acute myeloid leukaemiaFDA 2000
Alemtuzumab (Campath)Millennium/ Ilex Partners LPHumanized Ig anti CD52; chronic lymphocitic leukaemiaFDA 2001
EMEA 2001
Adalimumab (Humira)Abbott LaboratoriesHuman anti TNF- . Rheumatoid arthritisFDA 2002
EMEA 2003
Ibritumomab Tiuxetan (Zevalin)IDEC Pharmaceuticals Corp.Mouse Ig-Itrio 90 anti CD20. Non-Hodgkin lymphomaFDA 2002
EMEA 2004
Omalizumab (Xolair)Genentech Inc./RocheHumanized IgE. Severe asthmaFDA 2003
EMEA 2005
Tositumomab (Bexxar)GlaxoSmithKlineMurine Ig-Iodo131 anti CD20. Non-Hodgkin lymphomaFDA 2003
Efalizumab (Raptiva)Genentech Inc./RocheHumanized Ig anti-CD11aFDA 2003
Cetuximab (Erbitux)ImClone Systems/ Bristol-Nyers Squibb/Merck KgaAIgG1 directed against EGFR; colorectal tumourFDA 2004
Bevacizumab (Avastin)Genentech Inc.Humanized anti VEG; tumoursFDA 2004
EMEA 2005
Natalizumab (Tysabri)Biogen IdecHumanized anti CD49d. Multiple Sclerosis, Chron’s diseaseFDA 2006
EMEA 2006
Panibizumab (Lucentis)Genentech Inc.Humanized anti VEGF-A. Wet Macular DegenerationFDA 2006
EMEA 2007
Panimumab (Vectibix)AmgenHuman anti EGFR (epidermal growth factor receptor). Metastatic colorectal carcinomaFDA 2006
Eculizumab (Soliris)Alexion Pharmaceuticals Inc.Humanized anti CD59. Paroxysmmal nocturnal hemoglobinuriaFDA 2007
EMEA 2007
Certolizumab Pegol (Cimzia)UCB PharmaHumanized Fab anti-TNF- . Morbus Chron, rheumatoid arthritisFDA 2008
Golimumab (Simponi)Centocor (Johnson & Johnson)Human anti TNF- . Rheumatoid psoriatic arthritis, ctiveAnkylosing spondylitisFDA 2009